On December 1, 2023 Mammogen, a pioneering leader in women’s health and a subsidiary of early detection parent company, IVBH, reported groundbreaking clinical data at the 2023 San Antonio Breast Cancer Symposium (SABCS) (Press release, Mammogen, DEC 1, 2023, View Source [SID1234638099]). The poster, titled "Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer," showcases the strength and innovation of Mammogen’s proprietary genTRU-breast clinical assay.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Session Details:
Presentation ID: PO1-28-06
Abstract Title: Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer.
Session: Poster Session 1
Date: Wednesday, December 6, 2023
Time: 12:00 PM – 2:00 PM
Location: Henry B. Gonzalez Convention Center, San Antonio, Texas
This presentation follows Mammogen’s successful CLIA validation of the genTRU-breast assay, announced last month, a landmark achievement for the company and a transformative milestone in early-stage breast cancer detection.
Elizabeth Cormier-May, CEO of Mammogen, commented, "This data is a testament to our commitment to unlocking the quality-of-life preservation that exists in the earliest stages of breast cancer. The statistically significant >99% sensitivity and 89% specificity in stage I breast cancer, achieved during CLIA validation of our novel real-time qPCR assay, reinforces Mammogen’s position as a leader in accurate, affordable, scalable, and socially responsible diagnostics in women’s health."